Drugs.com - Clinical Trials

U.S. FDA Grants Orphan Drug Designation to Ariceum Therapeutics’ Proprietary Radiopharmaceutical Cancer Therapy

Berlin, Germany, 6 February 2025 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food and Drug...

Feb 10, 2025 - 06:24
 0
U.S. FDA Grants Orphan Drug Designation to Ariceum Therapeutics’ Proprietary Radiopharmaceutical Cancer Therapy
Berlin, Germany, 6 February 2025 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food and Drug...
Read More

Tags:

Previous Article

Can the nuclear industry find a better way to build?

Next Article

Intimiti Australia appoints Simon Pereira as Chief Marketing Officer

Related Posts

LimmaTech Awarded FDA Fast Track Designation for Vaccine Candidate Against Staphylococcus aureus

LimmaTech Awarded FDA Fast Track Designation for Vaccin...

Feb 9, 2025  0

Boehringer Provides Update on Iclepertin Phase III Program in Schizophrenia

Boehringer Provides Update on Iclepertin Phase III Prog...

Feb 9, 2025  0

Findings From Pivotal Nipocalimab Phase 3 Study in a Broad Antibody Positive Population of People Living with Generalized Myasthenia Gravis (gMG) Published in The Lancet Neurology

Findings From Pivotal Nipocalimab Phase 3 Study in a Br...

Feb 9, 2025  0